keyword
MENU ▼
Read by QxMD icon Read
search

immunotherapy allergy

keyword
https://www.readbyqxmd.com/read/29332094/low-dose-oral-immunotherapy-using-low-egg-allergen-cookies-for-severe-egg-allergic-children-reduces-allergy-severity-and-affects-allergen-specific-antibodies-in-serum
#1
Akihiro Maeta, Marin Matsushima, Nozomi Muraki, Mariko Asano, Yuri Takaoka, Makoto Kameda, Kyoko Takahashi
BACKGROUND: We evaluated the safety and efficacy of low-egg-allergen cookies (LAC) as low-dose oral immunotherapy (OIT) in children with severe egg allergy. We also examined the relationship between mild desensitization by low-dose OIT and serum biomarkers of allergy. METHODS: We enrolled 13 children with egg allergy who could not receive OIT with hard-boiled egg white (EW). For 11 participants, OIT was carried out using LAC for 3-4 months. Open food challenges with hard-boiled EW and blood samplings were performed before and after OIT...
January 13, 2018: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/29331065/component-resolved-diagnostics-to-direct-in-venom-immunotherapy-important-steps-towards-precision-medicine
#2
Simon Blank, Maria Beatrice Bilò, Markus Ollert
Stings of Hymenoptera can induce IgE-mediated systemic and even fatal allergic reactions. Venom-specific immunotherapy (VIT) is the only disease-modifying and curative treatment of venom allergy. However, choosing the correct venom for VIT represents a necessary prerequisite for efficient protection against further anaphylactic sting reactions after VIT. In the past, therapeutic decisions based on the measurement of specific IgE (sIgE) levels to whole venom extracts were not always straightforward, especially when the patient was not able to identify the culprit insect...
January 13, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29329957/safety-and-tolerability-of-a-novel-polyclonal-human-anti-mers-coronavirus-antibody-produced-from-transchromosomic-cattle-a-phase-1-randomised-double-blind-single-dose-escalation-study
#3
John H Beigel, Jocelyn Voell, Parag Kumar, Kanakatte Raviprakash, Hua Wu, Jin-An Jiao, Eddie Sullivan, Thomas Luke, Richard T Davey
BACKGROUND: Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic options are absent. We report the safety of a fully human polyclonal IgG antibody (SAB-301) produced from the hyperimmune plasma of transchromosomic cattle immunised with a MERS coronavirus vaccine...
January 9, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29319884/similar-localization-of-conformational-ige-epitopes-on-the-house-dust-mite-allergens-der-p-5-and-der-p-21-despite-limited-ige-cross-reactivity
#4
M Curin, T Garmatiuk, Y Resch-Marat, K W Chen, G Hofer, K Fauland, W Keller, W Hemmer, S Vrtala, M Focke-Tejkl, R Valenta
BACKGROUND: Due to high IgE recognition frequency and high allergenic activity, Der p 5 and Der p 21 are clinically important house dust mite (HDM) allergens. The objective of this study was to characterise the immunodominant IgE epitopes of Der p 5 and Der p 21 responsible for their high allergenic activity. METHODS: A panel of 12 overlapping peptides spanning the Der p 5 and Der p 21 sequence were synthesized to search for sequential IgE epitopes by direct testing for allergic patients ' IgE reactivity...
January 10, 2018: Allergy
https://www.readbyqxmd.com/read/29319881/systemic-il-2-anti-il-2ab-complex-combined-with-sublingual-immunotherapy-suppresses-experimental-food-allergy-in-mice-through-induction-of-mucosal-regulatory-t-cells
#5
Paola L Smaldini, Fernando Trejo, José L Cohen, Eliane Piaggio, Guillermo H Docena
Therapeutic tolerance restoration has been proven to modify food allergy in patients and animal models and although sublingual immunotherapy (SLIT) has showed promise, combined therapy may be necessary to achieve a strong and long-term tolerance. In this work, we combined SLIT with systemic administration of IL-2 associated with an anti-IL-2 monoclonal antibody (IL-2/anti-IL-2Ab complex or IL-2C) to reverse the IgE-mediated experimental allergy. Balb/c mice were sensitized with cholera toxin and milk proteins and orally challenged with allergen to elicit hypersensitivity reactions...
January 10, 2018: Allergy
https://www.readbyqxmd.com/read/29318625/consensus-document-on-dog-and-cat-allergy
#6
REVIEW
Ignacio Davila, Javier Domínguez-Ortega, Ana Mª Navarro Pulido, Alicia Alonso, Dario Antolin-Amerigo, Eloina González-Mancebo, Cristina Martin Garcia, Beatriz Nuñez-Acevedo, Nieves Prior, Marta Reche, Ana Rosado, Javier Ruiz-Hornillos, María Cesárea Sánchez, Miguel Torrecillas
The prevalence of sensitisation to dogs and cats varies by country, exposure time and predisposition to atopy. It is estimated that, 26% of European adults coming to the clinic for suspected allergy to inhalant allergens are sensitised to cats and 27% to dogs. This document is intended to be a useful tool for clinicians involved in the management of people with dog or cat allergy. It was prepared from a consensus process based on the RAND/UCLA method. Following a literature review, it proposes various recommendations concerning the diagnosis and treatment of these patients, grounded in evidence and clinical experience...
January 10, 2018: Allergy
https://www.readbyqxmd.com/read/29315922/the-use-of-omalizumab-in-allergen-immunotherapy
#7
Jennifer A Dantzer, Robert A Wood
Although omalizumab (anti-IgE) is currently only approved for the treatment of asthma and chronic idiopathic urticaria, it has also been studied as an off-label treatment for numerous allergic conditions, including use as an adjunct to allergen immunotherapy in the treatment of allergic rhinitis, asthma, venom hypersensitivity, and food allergy. We conducted a review of publications involving the use of omalizumab with allergen immunotherapy, by searching PubMed with key search terms of "omalizumab" and "immunotherapy...
January 5, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29301162/milbenallergie-im-hno-bereich-bedeutung-diagnostik-und-therapieoptionen
#8
Ludger Klimek, Moritz Gröger, Sven Becker
Allergic rhinitis (AR) affects ca. 20% of the population. Approximately one third of patients affected by AR are suffering from perennial rhinitis due to mite allergy. Perennial rhinitis is the form of the disease that is most frequently associated with other allergy-related comorbidities such as asthma and atopic dermatitis, sleep disorders, chronic sinusitis, eustachian tube dysfunction and others.The often non-specific symptoms and the insidious course may lead to misinterpretations in diagnosing the disease...
January 2018: Laryngo- Rhino- Otologie
https://www.readbyqxmd.com/read/29295630/the-economic-advantage-of-allergen-immunotherapy-over-drug-treatment-in-respiratory-allergy
#9
Cristoforo Incorvaia, Bruna L Gritti, Erminia Ridolo
No abstract text is available yet for this article.
January 3, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29290503/-evaluation-of-sensitization-to-der-p-1-and-der-p-2-in-a-pediatric-population-of-the-north-of-portugal
#10
Sara Peixoto, Joana Soares, Tânia Monteiro, Marisa Carvalho, Marinela Santos, Carla Simões, Márcia Quaresma
INTRODUCTION: In Portugal, data on the role of Der p 1 and Der p 2 in patients with house dust mite (HDM) allergy are scarce. Allergen-specific immunotherapy (sIT) is the only treatment that improves symptoms, reduces the need for pharmacological therapy and modifies the natural history of the disease. With this study, the authors aim to understand the local epidemiology and to clarify if the molecular assay of major allergens is advantageous in deciding and/or modifying the decision to initiate sIT in children with clinical indication which are sensitized to Dermatophagoides pteronyssinus...
December 28, 2017: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
https://www.readbyqxmd.com/read/29279062/comparison-of-the-effect-of-5-grass-pollen-sublingual-immunotherapy-tablets-and-drops-in-children-with-rhinoconjunctivitis
#11
Joanna Jerzynska, Wlodzimierz Stelmach, Pawel Majak, Rafal Stelmach, Anna Janas, Iwona Stelmach
BACKGROUND: One of the most important aspects of sublingual immunotherapy (SLIT) is the regimen of administration. AIM: To find any differences in symptom-medication scores between the two groups of SLIT tablets and drops, given pre-coseasonally (starting 8 weeks before the pollen season) in children with rhinoconjunctivitis allergy to grass pollen. The secondary outcome were the differences in lung function and induction of T-regulatory forkhead box P3 (FOXP3) positive cells...
January 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29258788/anaphylactic-reactions-after-discontinuation-of-hymenoptera-venom-immunotherapy-a-clonal-mast-cell-disorder-should-be-suspected
#12
Patrizia Bonadonna, Roberta Zanotti, Mauro Pagani, Massimiliano Bonifacio, Luigi Scaffidi, Elisa Olivieri, Maurizio Franchini, Federico Reccardini, Maria Teresa Costantino, Chiara Roncallo, Marina Mauro, Elisa Boni, Fabio Lodi Rizzini, Maria Beatrice Bilò, Anna Rosaria Marcarelli, Giovanni Passalacqua
BACKGROUND: Up to 75% of patients with severe anaphylactic reactions after Hymenoptera sting are at risk of further severe reactions if re-stung. Venom immunotherapy (VIT) is highly effective in protecting individuals with ascertained Hymenoptera venom allergy (HVA) and previous severe reactions. After a 3- to 5-year VIT course, most patients remain protected after VIT discontinuation. Otherwise, a lifelong treatment should be considered in high-risk patients (eg, in mastocytosis). Several case reports evidenced that patients with mastocytosis and HVA, although protected during VIT, can re-experience severe and sometimes fatal reactions after VIT discontinuation...
December 16, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29249132/shrimp-allergy-beyond-avoidance-diet
#13
D El-Qutob
Currently, the management of people diagnosed with shellfish allergy relies on the avoidance of those foods. HDM immunotherapy has been reported to induce both shrimp allergy in non-allergic patients, and shrimp tolerance in shrimp-allergic patients. This article summarizes therapeutic options other than avoidance diet for shrimp allergic patients available once the diagnostic is established, such as production of hypoallergenic shrimp, use of immunotherapy with modified allergens, probiotics and Chinese herbal formulations...
November 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29242014/anti-ige-treatment-with-oral-immunotherapy-in-multifood-allergic-participants-a-double-blind-randomised-controlled-trial
#14
Sandra Andorf, Natasha Purington, Whitney M Block, Andrew J Long, Dana Tupa, Erica Brittain, Amanda Rudman Spergel, Manisha Desai, Stephen J Galli, Kari C Nadeau, R Sharon Chinthrajah
BACKGROUND: Despite progress in single food oral immunotherapy, there is little evidence concerning the safety and efficacy of treating individuals with multiple food (multifood) allergies. We did a pilot study testing whether anti-IgE (omalizumab) combined with multifood oral immunotherapy benefited multifood allergic patients. METHODS: We did a blinded, phase 2 clinical trial at Stanford University. We enrolled participants, aged 4-15 years, with multifood allergies validated by double-blind, placebo-controlled food challenges to their offending foods...
December 11, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29234055/oral-immunotherapy-combined-with-omalizumab-for-high-risk-cow-s-milk-allergy-a-randomized-controlled-trial
#15
Masaya Takahashi, Kazuhiko Soejima, Shoichiro Taniuchi, Yasuko Hatano, Sohsaku Yamanouchi, Hideki Ishikawa, Makoto Irahara, Youhei Sasaki, Hiroshi Kido, Kazunari Kaneko
We evaluated the efficacy and safety of oral immunotherapy (OIT) combined with 24 weeks of omalizumab (OMB) at inducing desensitization in children with cow's milk allergy (CM) compared with an untreated group. The present study was a prospective randomized controlled trial. Sixteen patients (age, 6-14 years) with high IgE levels to CM were enrolled in the present study. Patients were randomized 1:1 to receive OMB-OIT group or untreated group. The primary outcome was the induction of desensitization at 8 weeks after OMB was discontinued in OMB-OIT treated group and at 32 weeks after study entry...
December 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29233867/antibody-drug-improves-desensitisation-with-oral-immunotherapy-in-children-with-multifood-allergy-study-finds
#16
Susan Mayor
No abstract text is available yet for this article.
December 12, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29233461/long-term-safety-of-subcutaneous-immunotherapy-with-to-204-in-japanese-patients-with-house-dust-mite-induced-allergic-rhinitis-and-allergic-bronchial-asthma-multicenter-open-label-clinical-trial
#17
Takao Fujisawa, Terufumi Shimoda, Keisuke Masuyama, Kimihiro Okubo, Kohei Honda, Mitsuhiro Okano, Toshio Katsunuma, Atsuo Urisu, Yasuto Kondo, Hiroshi Odajima, Kazuyuki Kurihara, Makoto Nagata, Masami Taniguchi, Shoichiro Taniuchi, Satoru Doi, Tomoshige Matsumoto, Shoji Hashimoto, Akihiko Tanaka, Kensuke Natsui, Nahoko Abe, Hideki Ozaki
BACKGROUND: To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial. METHODS: Japanese patients aged 5-65 years were eligible for the study, if they had HDM-induced allergic rhinitis (AR), allergic bronchial asthma (BA), or both. TO-204 was administered in a dose titration scheme, and the maintenance dose was determined according to the predefined criteria...
December 7, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/29214012/evidence-of-the-efficacy-and-safety-of-house-dust-mite-subcutaneous-immunotherapy-in-elderly-allergic-rhinitis-patients-a-randomized-double-blind-placebo-controlled-trial
#18
Andrzej Bożek, Krzysztof Kołodziejczyk, Renata Kozłowska, Giorgio Walter Canonica
Background: Allergen specific immunotherapy (AIT) in elderly patients is controversial, and there is still little evidence supporting the safety and efficacy of this treatment in this population. The study objective was to evaluate the safety and efficacy of AIT for house dust mite allergens in patients over 65 years of age with allergic rhinitis (AR) and a documented allergy to house dust mites. The primary endpoint was the change from baseline in the mean average adjusted symptom score (AAdSS) and the total combined rhinitis score (TCRS) difference in the least square means for the label compared to placebo...
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/29205393/eaaci-guidelines-on-allergen-immunotherapy-ige-mediated-food-allergy
#19
G B Pajno, M Fernandez-Rivas, S Arasi, G Roberts, C A Akdis, M Alvaro-Lozano, K Beyer, C Bindslev-Jensen, W Burks, M Ebisawa, P Eigenmann, E Knol, K C Nadeau, L K Poulsen, R van Ree, A F Santos, G du Toit, S Dhami, U Nurmatov, Y Boloh, M Makela, L O'Mahony, N Papadopoulos, C Sackesen, I Agache, E Angier, S Halken, M Jutel, S Lau, O Pfaar, D Ryan, G Sturm, E-M Varga, R G van Wijk, A Sheikh, A Muraro
Food allergy can result in considerable morbidity, impairment of quality of life, and healthcare expenditure. There is therefore interest in novel strategies for its treatment, particularly food allergen immunotherapy (FA-AIT) through the oral (OIT), sublingual (SLIT), or epicutaneous (EPIT) routes. This Guideline, prepared by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force on Allergen Immunotherapy for IgE-mediated Food Allergy, aims to provide evidence-based recommendations for active treatment of IgE-mediated food allergy with FA-AIT...
September 27, 2017: Allergy
https://www.readbyqxmd.com/read/29205109/new-treatments-for-allergy-advances-in-peptide-immunotherapy
#20
David Calzada, Selene Baos, Lucia Cremades, Blanca Olombrada Cardaba
BACKGROUND: Nowadays, allergen-specific immunotherapy (AIT) is the only treatment able to modulate the course of allergic diseases. Although it has been applied for the last 100 years, treatment with whole allergen extracts is not without its drawbacks: AIT can cause local and systemic adverse events and may produce new IgE sensitization against other allergens present in the extract. Furthermore, the lengthy treatment duration (3-5 years), frequent administration, and high cost of treatment are other disadvantages...
November 30, 2017: Current Medicinal Chemistry
keyword
keyword
115750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"